tika1 Friday, 04/13/18 09:10:07 AM Re: DewDiligence post# 20 Post # of 66 Dew, Is there any hope for success of this trial after high profile INCY failure? What is your take on SNDX current weakness? Oral Presentations: Title: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial Presenter: Anthony W. Tolcher, M.D. Category: Clinical Trials Session: Biomarkers in Immuno-oncology Abstract Number: CT179 Location: N Hall C - McCormick Place North (Level 1) Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T. Please do your own due diligence. My post is for information only.